1/2 clinical coordinating center for the spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction study (spirrit-EX)

Active Cooperative Agreement Awarded Last action

Award ID
UH3HL173571
Recipient
Awarding agency
Obligated
$1,288,714

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 60% complete
Place of performance
Durham, NC 27710, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Over half of the 6.7 million adults with heart failure in the united states have a normal or near-normal left ventricular ejection fraction, or heart failure with preserved ejection fraction (hfpef). The prevalence of hfpef is increasing over time, due to ageing of the population and other factors. Morbidity and mortality for patients with hfpef remains high; rates are similar to those observed in HF with reduced ejection fraction. Poor outcomes in hfpef are related to a lack of evidence-based therapeutic options. There is an urgent need to efficiently conduct large, simple, streamlined trials with clinically relevant endpoints comprised of therapeutic interventions for hfpef patients. Mineralocorticoid receptor antagonists (including spironolactone) present one promising treatment for hfpef. In clinical trials of participants with HF with reduced ejection fraction, mineralocorticoid receptor antagonists have consistently demonstrated their ability to improve symptoms, and reduce mortality and hospitalizations. However, the topcat trial was the largest study of mineralocorticoid receptor antagonists in hfpef. In topcat, spironolactone did not significantly reduce the primary outcome (a composite of cardiovascular death, aborted cardiac arrest, or hospitalization for HF) relative to placebo, but did reduce a secondary endpoint of HF hospitalization (HR 0.83, 95% CI 0.69-0.99, p=0.04). A post-hoc regional analysis of topcat, limited to north and south america, found that spironolactone reduced the primary endpoint (HR 0.82, 95% CI 0.69-0.98) compared to placebo. Therefore, topcat demonstrated the potential promise of mineralocorticoid receptor antagonists in hfpef but was not definitive. The spirrit-hfpef (spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction) randomized clinical trial was funded in 2018 for 5 years and has now randomized >1900 participants. The primary aim of spirrit-hfpef is to test the hypothesis that use of spironolactone will reduce total HF events (total hospitalizations for HF and death from cardiovascular causes). Spirrit-hfpef will complete enrollment december 31, 2023. The current application for spirrit-EX is for a free-standing extension of the spirrit-hfpef trial to extend follow-up through 2025 and to allow for accrual of additional clinical events. The application will specifically support extended follow-up, secondary analyses (including a pre-specified meta-analysis of data from another ongoing hfpef clinical trial), dissemination of results, and closeout activities of participants previously randomized in spirrit-hfpef. Resolving whether spironolactone is beneficial in patients with hfpef would have tremendous public health implications.

Transactions

Action Obligated Date
Amendment $413,146
Amendment $22,362
Amendment $22,362
Amendment $332,946
Original award $497,898

Subawards

Subrecipient Amount Awarded
Region Uppsala Dcri #8735 spirrit-extend CCC $1,063,652
Regents Of The University Of Michigan $40,715

Quick answers

Who received award UH3HL173571?

UH3HL173571 was awarded to Duke University by National Heart Lung and Blood Institute (National Institutes of Health) on June 1, 2024.

How much is award UH3HL173571 worth?

$1,288,714 has been obligated on UH3HL173571.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login